Portal de Periódicos da CAPES

P53 AND BCL-2 IMMUNOHISTOCHEMISTRY IN PRETREATMENT PROSTATE NEEDLE BIOPSIES TO PREDICT RECURRENCE OF PROSTATE CANCER AFTER RADICAL PROSTATECTOMY

1999; Lippincott Williams & Wilkins; Volume: 162; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(05)68095-0

1527-3792

G. Bennett Stackhouse, Isabell A. Sesterhenn, John J. Bauer, F. K. Mostofi, Roger R. Connelly, Shiv Srivastava, Judd W. Moul,

Prostate Cancer Diagnosis and Treatment

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Dec 1999P53 AND BCL-2 IMMUNOHISTOCHEMISTRY IN PRETREATMENT PROSTATE NEEDLE BIOPSIES TO PREDICT RECURRENCE OF PROSTATE CANCER AFTER RADICAL PROSTATECTOMY GEORGE B. STACKHOUSE, ISABELL A. SESTERHENN, JOHN J. BAUER, F. KASH MOSTOFI, ROGER R. CONNELLY, SHIV K. SRIVASTAVA, and JUDD W. MOUL GEORGE B. STACKHOUSEGEORGE B. STACKHOUSE , ISABELL A. SESTERHENNISABELL A. SESTERHENN , JOHN J. BAUERJOHN J. BAUER , F. KASH MOSTOFIF. KASH MOSTOFI , ROGER R. CONNELLYROGER R. CONNELLY , SHIV K. SRIVASTAVASHIV K. SRIVASTAVA , and JUDD W. MOULJUDD W. MOUL View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68095-0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Immunohistochemical staining of radical prostatectomy specimens for p53 and bcl-2 proteins has been shown to correlate with prostate specific antigen (PSA) recurrence in a series of patients at our institution. We analyzed the relationship between staining of diagnostic prostate needle biopsies for p53 and bcl-2, and PSA recurrence. Materials and Methods: From 1986 to 1993, 335 radical prostatectomies were performed at our hospital. Of the prostatectomy specimens 199 had been evaluated for p53 and bcl-2 proteins in a prior series. Of 139 patients with biopsy material available for analysis 129 had enough for evaluation of 1 or both markers. Prospectively obtained clinical followup data were available, with a mean followup of 6 years. Commercially available antibodies were used for immunohistochemical staining. Results: The overall PSA recurrence rate was 37.6% for 199 radical prostatectomy cases and 37.9% for 129 with biopsy immunohistochemical staining. Staining of prostatectomies correlated well with PSA recurrence for p53 (p = 0.004) and bcl-2 (p = 0.001). However, biopsy staining did not correlate with prostatectomy staining or PSA recurrence for either marker. Conclusions: The p53 and bcl-2 biomarkers appear to be important to predict recurrence of prostate cancer when prostatectomy specimens are analyzed but this usefulness is not apparent with immunohistochemical staining of prostate biopsies. This difference may reflect sampling error and/or the heterogeneous nature of prostate cancers, and deserves further study. References 1 : Cancer Statistics, 1998. CA1998; 48: 6. Google Scholar 2 : The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J. Urol.1994; 152: 1910. Link, Google Scholar 3 : Screening for prostate cancer. Lancet1997; 349: 1098. Google Scholar 4 : Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Ann. Intern. Med.1997; 126: 468. Google Scholar 5 : Grading prostate cancer. Amer. J. Clin. Path.1994; 102: S3. Google Scholar 6 : Histopathology of localized prostate cancer. Consensus conference on diagnosis and prognostic parameters in localized prostate cancer. Stockholm, Sweden, May 12–13, 1993. Scand. J. Urol. Nephrol.1994; 162: 7. Google Scholar 7 : National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J. Urol.1994; 152: 1817. Link, Google Scholar 8 : The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol.1994; 152: 1821. Link, Google Scholar 9 : 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol.1994; 152: 1837. Link, Google Scholar 10 : Impact of radical prostatectomy in the management of clinically localized disease. J. Urol.1994; 152: 1826. Link, Google Scholar 11 : Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol.1994; 152: 1850. Link, Google Scholar 12 : Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol.1996; 156: 1511. Link, Google Scholar 13 : Combined analysis with bcl-2 and p-53 Immunostaining predicts poorer prognosis in prostatic carcinoma. J. Urol.1997; 158: 2278. Link, Google Scholar 14 : Suppression of human colorectal carcinoma cell growth by wild-type p53. Science1990; 249: 912. Google Scholar 15 : Participation of p53 protein in the cellular response to DNA damage. Cancer Res.1991; 51: 6304. Google Scholar 16 : p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature1993; 362: 84. Google Scholar 17 : The p53 tumor suppresser gene. Nature1991; 351: 453. Google Scholar 18 : p53 Mutations in human cancers. Science1991; 253: 49. Google Scholar 19 : p53 Oncogene mutations in human prostate cancer specimens. J. Urol.1994; 151: 492. Link, Google Scholar 20 : Mutant p53 expression in prostate carcinoma. Prostate1993; 22: 23. Google Scholar 21 : Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Amer. J. Path.1995; 147: 92. Google Scholar 22 : Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol.1995; 154: 414. Link, Google Scholar 23 : Prognostic significance of bcl-2 in clinically localized prostate cancer. Amer. J. Path.1996; 148: 1557. Google Scholar 24 : Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum. Path.1995; 26: 106. Google Scholar 25 : p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J. Natl. Cancer Inst.1997; 89: 158. Google Scholar 26 : p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer. Eur. Urol.1996; 30: 65. Google Scholar 27 : Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1–2 M0 prostatic adenocarcinoma. Int. J. Cancer1994; 58: 303. Google Scholar 28 : An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res.1996; 56: 3814. Google Scholar 29 : bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell1991; 67: 879. Google Scholar 30 : Cloning the chromosomal breakpoint of t(l4: 18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell1984; 14: 889. Google Scholar 31 : Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res.1992; 52: 6940. Google Scholar 32 : Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Amer. J. Path.1993; 143: 390. Google Scholar 33 : P53 and bcl-2 Immunohistochemical alteration in prostate cancer treated with radiation therapy. Urology1998; 51: 346. Google Scholar 34 : Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in KI-67 labeling index, p53, and bcl-2 immunoreactivity. J. Urol.1998; 159: 1437. Link, Google Scholar 35 : The expression of waf-1, p53, and bcl-2 in prostatic adenocarcinoma. Brit. J. Urol.1997; 79: 190. Google Scholar 36 : Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J. Urol.1999; 162: 394. Link, Google Scholar From the Department of Surgery, Urology Service, Walter Reed Army Medical Center and the Department of Genitourinary Pathology, Armed Forces Institute of Pathology, Washington, D. C., and the Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByHirata H, Hinoda Y, Kikuno N, Suehiro Y, Shahryari V, Ahmad A, Tabatabai Z, Igawa M and Dahiya R (2018) Bcl2 −938C/A Polymorphism Carries Increased Risk of Biochemical Recurrence After Radical ProstatectomyJournal of Urology, VOL. 181, NO. 4, (1907-1912), Online publication date: 1-Apr-2009.Hirata H, Hinoda Y, Nakajima K, Kikuno N, Suehiro Y, Tabatabai Z, Ishii N and Dahiya R (2018) The bcl2 −938CC Genotype Has Poor Prognosis and Lower Survival in Renal CancerJournal of Urology, VOL. 182, NO. 2, (721-727), Online publication date: 1-Aug-2009.Gomez C, Gomez P, Knapp J, Jorda M, Soloway M and Lokeshwar V (2018) Hyaluronic Acid and HYAL-1 in Prostate Biopsy Specimens: Predictors of Biochemical RecurrenceJournal of Urology, VOL. 182, NO. 4, (1350-1356), Online publication date: 1-Oct-2009.Abaza R, Diaz L, Laskin W and Pins M (2018) Prognostic Value of DNA Ploidy, bcl-2 and p53 in Localized Prostate Adenocarcinoma Incidentally Discovered at Transurethral ProstatectomyJournal of Urology, VOL. 176, NO. 6, (2701-2705), Online publication date: 1-Dec-2006.WU T, HSU Y, LEE J and HUANG J (2018) The Role of p53, bcl-2 and E-Cadherin Expression in Predicting Biochemical Relapse for Organ Confined Prostate Cancer in TaiwanJournal of Urology, VOL. 170, NO. 1, (78-81), Online publication date: 1-Jul-2003.FEBBO P and SELLERS W (2018) Use of Expression Analysis to Predict Outcome After Radical ProstatectomyJournal of Urology, VOL. 170, NO. 6S, (S11-S20), Online publication date: 1-Dec-2003.THOMAS G, SCHRAGE M, ROSENFELT L, KIM J, SALUR G, deKERNION J, DOREY F, SAID J and REITER R (2018) PREOPERATIVE PROSTATE NEEDLE BIOPSY p27 CORRELATES WITH SUBSEQUENT RADICAL PROSTATECTOMY p27, GLEASON GRADE AND PATHOLOGICAL STAGEJournal of Urology, VOL. 164, NO. 6, (1987-1991), Online publication date: 1-Dec-2000.BORRE M, STAUSBØL-GRØN B and OVERGAARD J (2018) p53 ACCUMULATION ASSOCIATED WITH bcl-2, THE PROLIFERATION MARKER MIB-1 AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER SUBJECTED TO WATCHFUL WAITINGJournal of Urology, VOL. 164, NO. 3 Part 1, (716-721), Online publication date: 1-Sep-2000. Volume 162Issue 6December 1999Page: 2040-2045 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.Keywordsneoplasm stagingprotein p53c-bcl-2 proteinsprostate neoplasmsprostatectomyMetricsAuthor Information GEORGE B. STACKHOUSE More articles by this author ISABELL A. SESTERHENN More articles by this author JOHN J. BAUER More articles by this author F. KASH MOSTOFI More articles by this author ROGER R. CONNELLY More articles by this author SHIV K. SRIVASTAVA More articles by this author JUDD W. MOUL More articles by this author Expand All Advertisement PDF DownloadLoading ...